Chardan Capital Maintains Buy on Sonnet BioTherapeutics, Lowers Price Target to $14

Benzinga · 05/11/2023 09:21
Chardan Capital analyst Keay Nakae maintains Sonnet BioTherapeutics (NASDAQ:SONN) with a Buy and lowers the price target from $17 to $14.